Gilead Sciences gets exclusive global license to develop, commercialize Xilio tumor-activated IL-12
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok